Parathyroid Hormone (PTH) (MRQ-31) Mouse Monoclonal Antibody

The rate of parathormone secretion is directly responsive to the level of calcium in the serum, and indeed the cytoplasm, of parathyroid cells, as has been shown by studies both in vivo and in vitro (Brown et al, 1982). Recent in vitro studies of osteoclast turnover suggest that both PTH and PTH-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells (Chen et al, 2002)

Surgical pathologists are familiar with the ability of parathyroid proliferations to assume a variety of histological guises, posing difficulty to categorize any given lesion as hyperplastic, adenomatous or carcinomatous in nature (Wick et al, 1997). This is usually resolved with macroscopic appearance of the remaining parathyroid glands as assessed by the surgeon. The role of the surgical pathologist is to identify the lesion as parathyroid in nature and to assess whether it is normocellular or hypercellular. Although easily accomplished in the majority of instances, rare examples of parathyroid hyperplasia/adenoma showing a follicular/trabecular arrangement may cause concern over the alternative diagnosis of a thyroid adenoma. This becomes more pertinent when the parathyroid lesion abuts into the thyroid gland or lies within the thyroid capsule. Immunostaining for thyroglobulin and parathyroid hormone (PTH) is especially useful to resolve the problem (Permanetter et al, 1983). Nevertheless, caution should be exercised since parathyroid cells often discharge their hormonal product almost as soon as it is packaged in the cytoplasm, resulting in false-negative anti-PTH immunostaining, although the cells are biologically synthetic (Wick et al, 1997)

Anti-PTH antibody is also useful to distinguish parathyroid hyperplasia/neoplasms from thyroid and metastatic neoplasms (Wick et al, 1997); although the pathologist is typically aware of the preoperative hypercalcemic status. Occasionally when the surgeon does not supply this information PTH immunohistochemistry is essential. Even more problematic, are situations in which clear cell parathyroid carcinomas are nonsecretory without an abnormality in mineral metabolism (Aldinger et al, 1982). In such situations, metastatic renal cell carcinoma or metastatic clear cell carcinoma of the lung is evident warranting PTH immunohistochemistry to arrive at the correct diagnosis (Wick et al, 1997). The other instance in which anti-PTH antibodies are useful is in the consideration of parathyroid carcinomas located primarily in the anterior mediastinum (intrathymically). In this situation distinction from primary thymic metastatic carcinomas, non-Hodgkin′s lymphoma and germ cell tumors is necessary (Murphy et al, 1986).

The diagnosis of the majority of parathyroid proliferation may be accomplished with an adequate history, biochemistry profile, and histomorphological assessment; however, rare instances in which the tumors have an abnormal location, clear cell morphology, or a non-secretory may result in erroneous diagnoses, warranting anti-PTH immunohistochemistry.

Parathyroid Hormone (PTH) Positive Control Slides, Product No. 310S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany